Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 100 mg/4 mL [25 mg/mL] or 400 mg/16 mL [25 mg/mL]) |
| Drug Class | Vascular endothelial growth factor (VEGF) inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil based chemotherapy for first- or second-line treatment
- Indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidineirinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen
- Indicated for the treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment
- Indicated for the treatment of recurrent glioblastoma in adults
- Indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa
- Indicated for the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan
- Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection
- Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens
- Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease
- Indicated for the treatment of hepatocellular Carcinoma (HCC): in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy.
Latest News
Summary
- This summary is based on the review of 127 systematic review(s)/meta-analysis(es). [1-126]
- In meningioma patients, the mean progression-free survival (PFS) and overall survival (OS) were 19.1 ± 4.7 months and 23.9 ± 8.4 months, respectively, with six-month, twelve-month, and twenty-four-month PFS rates at 0.80, 0.66, and 0.25, and OS rates at 0.89, 0.86, and 0.48, respectively; the response rate was 0.33 (95% confidence interval (CI): 0.14–0.60).
- In hepatocellular carcinoma (HCC), sorafenib combined with bevacizumab showed improved outcomes in Asian populations compared to other therapies, such as lenvatinib or atezolizumab with bevacizumab, following initial treatment with sorafenib.
- For non-small cell lung cancer (NSCLC), the combination of pemetrexed with bevacizumab was associated with improved overall survival (hazard ratio (HR) = 0.87) and PFS (HR = 0.63), although there was an increase in grade ≥3 adverse events with the combination.
- In epithelial ovarian cancer, combining bevacizumab with carboplatin and paclitaxel significantly improved PFS (HR: 0.73; 95% CI: 0.58, 0.92; p = 0.008) compared to carboplatin and paclitaxel alone.
- In HCC, common adverse events with treatments including bevacizumab were hypertension, non-central nervous system (CNS) bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria.
- For epithelial ovarian cancer, bevacizumab combined with carboplatin and paclitaxel resulted in a higher incidence of adverse events, notably hypertension, non-CNS bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria, compared to chemotherapy alone.
- In NSCLC, the combination of bevacizumab and pemetrexed led to an increase in grade ≥3 adverse events with an odds ratio of 2.15, indicating higher toxicity compared to pemetrexed monotherapy.
- In colorectal cancer, bevacizumab combined with chemotherapy was associated with an increase in grade ≥3 adverse events, including hypertension and gastrointestinal perforation, compared to monotherapy.
- In meningioma patients, bevacizumab showed high efficacy in refractory, high-grade, or neurofibromatosis-associated cases, with the study population consisting of 47.9% male patients.
- In HCC, sorafenib combined with bevacizumab yielded better outcomes in Asian populations, and in NSCLC, the combination of lenvatinib with programmed cell death protein 1 (PD-1) and locoregional therapy (LRT) demonstrated higher conversion to surgery rates and increased objective response rates in certain subgroups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Avastin (bevacizumab) Prescribing Information. | 2022 | Genentech, Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines. | 2024 | Journal of Gynecologic Oncology |
| Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma | 2022 | Journal of Neuro-oncology |
| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. | 2022 | Journal of the National Comprehensive Cancer Network |
| Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. | 2021 | Journal of the National Comprehensive Cancer Network |
| Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. | 2020 | Annals of Hepatology |
| PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline | 2020 | Journal of Clinical Oncology : Official Journal of the American Society of |